Lead: A U.S. district court in Massachusetts on Monday temporarily halted a series of vaccine-policy changes put in place by Health Secretary Robert F. Kennedy Jr., reversing decisions made by his appointees to the Advisory Committee on Immunization Practices (ACIP) and preventing the panel from meeting as planned. Judge Brian Murphy found the administration had bypassed required scientific procedures in altering the childhood immunization schedule and the CDC’s guidance. The injunction stops changes that would have reduced routine childhood immunizations and restricted access to certain Covid shots while the dispute proceeds through the courts. The ruling is expected to be appealed, intensifying a legal and public-health showdown over federal vaccine policymaking.
Key Takeaways
- Judge Brian Murphy issued a preliminary injunction on March 16, 2026, blocking implementation of decisions made by Secretary Robert F. Kennedy Jr. and his ACIP appointees.
- The suit was filed in July 2025 by six medical organizations, including the American Academy of Pediatrics; plaintiffs sought restoration of the prior immunization schedule.
- Court action reversed recent panel decisions and stopped an ACIP meeting that had been scheduled for later in the week.
- Changes at issue included trimming the number of diseases on the routine childhood schedule from 17 to 11 and rescinding universal newborn hepatitis B recommendations.
- A January 2026 memo from acting CDC director Jim O’Neill that promulgated a new schedule was found to have bypassed ACIP and was ruled unlawful.
- The ruling emphasizes that ACIP’s scientific-review procedures are codified by law and cannot be disregarded without violating administrative requirements.
- The decision arrives amid sharp disputes between public-health institutions and the Department of Health and Human Services under Secretary Kennedy, who has a long record of vaccine skepticism.
Background
ACIP is the federal advisory committee that reviews evidence and issues vaccine recommendations that inform state immunization requirements and insurance coverage. For decades ACIP’s work has followed methodical evidence review, public meetings, and external expert input; states typically use ACIP recommendations when setting school-entry vaccination rules. In June 2025, Secretary Kennedy removed the existing ACIP members and appointed a new slate of panelists aligned with his more skeptical stance on vaccines.
The new panel moved quickly, rescinding several longstanding recommendations in three meetings since the overhaul. Separately, in January 2026, Jim O’Neill, serving as acting CDC director, issued a revised childhood immunization schedule without full ACIP deliberation. Medical societies, practitioners and public-health foundations warned that rapid, unilateral changes risked undermining confidence in vaccines and could increase outbreaks of formerly controlled diseases.
Main Event
The lawsuit, brought by six medical organizations and later joined by an amicus brief from more than 100 public-health experts and groups, contended that the administration’s changes were “arbitrary and capricious” and violated statutory procedural safeguards. On March 16, Judge Murphy agreed that the administration had failed to follow required processes, writing that the January 2026 memo lacked sufficient consultation with ACIP and therefore was unlawful.
The court’s order temporarily reinstates the prior immunization schedule while legal challenges proceed and prevents the newly appointed ACIP members from meeting to implement further revisions. Plaintiffs had sought restoration of the vaccine recommendations in place before Secretary Kennedy began revising policy a year ago; the court’s decision grants that immediate relief pending further litigation.
Government attorneys argued during hearings that the administration’s choices reflected permissible policy differences and emphasized that states retain ultimate authority over which vaccines are mandatory. In court, the administration’s counsel asserted broad authority for the secretary and his appointees; Judge Murphy explicitly rejected the notion that the executive could act with unreviewable authority to abandon established scientific procedures.
Analysis & Implications
The ruling underscores the legal limits on administrative discretion where Congress and regulation prescribe procedural safeguards for scientific advisory panels. By invoking the Administrative Procedure Act and related statutes, the court reinforced that scientific advisory processes — including public deliberation and evidence review — are not optional preferences but legal requirements when federal recommendations will affect public health policy nationwide.
Practically, the injunction preserves the pre-2026 immunization schedule that many physicians, states and insurers pledged to follow. That reduces immediate risk of a patchwork of state-level policies and maintains insurance coverage norms tied to established ACIP guidance. However, the ruling does not resolve the underlying policy dispute; a successful appeal could restore the administration’s changes, while a final ruling for plaintiffs would set a precedent limiting future secretarial shortcuts.
Politically, the decision places the Kennedy-led Department of Health and Human Services at the center of a fraught national conversation about expertise, regulatory process and public trust. Public-health groups frame the ruling as a restoration of evidence-based decision-making; supporters of the administration argue it was correcting public mistrust and adapting policy to shifting attitudes. The legal process will likely take months, during which public communication and state-level decisions will shape vaccine uptake and disease risk.
Comparison & Data
| Metric | Pre-2026 Schedule | January 2026 Revisions |
|---|---|---|
| Routine diseases covered | 17 | 11 |
| Newborn Hepatitis B | Recommended for all newborns | Recommendation rescinded |
| Covid vaccine recommendation (children/pregnant) | Recommended as appropriate | Not recommended for healthy children or pregnant women |
The table summarizes the principal quantitative and categorical shifts challenged in court. Reductions from 17 to 11 diseases on the routine schedule and the withdrawal of universal newborn hepatitis B guidance were among the most consequential alterations cited by plaintiffs. Public-health experts warn that removing universal recommendations can lower uptake and erode herd immunity, especially when coupled with broader distrust. State vaccination requirements and insurance reimbursement typically follow ACIP guidance; therefore schedule changes have system-wide consequences beyond the advisory committee itself.
Reactions & Quotes
Plaintiff attorneys and medical organizations portrayed the ruling as a defense of scientific standards and public safety.
“This is a significant victory for public health, evidence-based medicine, the rule of law, and the American people.”
Richard Hughes, lead counsel for plaintiffs (legal representative)
Hughes spoke to reporters after the ruling, saying the decision preserves established protections while litigation continues and that plaintiffs view it as an immediate safeguard against what they characterized as dangerous policy shifts.
“We want to restore science to our nation’s vaccine decision-making and stop policies that risk outbreaks.”
Mark Del Monte, CEO, American Academy of Pediatrics (medical organization)
Del Monte emphasized that the academy had issued its own schedule to mirror prior CDC guidance and urged collaboration rather than courtroom battles. He warned of potential rises in disease if uptake declines.
“Letting an unqualified panel dictate vaccine policy is as reckless as letting amateur pilots run our aviation system.”
Dr. Tina Hartert, co-chair, American Thoracic Society vaccine advisory committee (medical expert)
Dr. Hartert and other scientific critics argued that the qualifications and processes required for federal advisory recommendations were being undermined, increasing the stakes for public safety.
Unconfirmed
- The timing and success of any government appeal remain uncertain; formal appeal filings are expected but not yet resolved.
- Claims that specific ACIP members stated Covid vaccines are “deadly” have been reported in some outlets but lack independently verified, attributable transcripts in the public record.
- The long-term impact on vaccine confidence nationwide is plausible but not yet measurable; surveillance data on uptake will be needed to confirm any sustained trend.
Bottom Line
The Massachusetts court’s decision is a decisive check on rapid administrative changes to vaccine policy that did not follow established scientific procedures. In the short term, it preserves the immunization recommendations physicians, insurers and states had been using and reduces immediate disruption to routine childhood vaccination programs.
Longer term, the dispute will shape both legal precedent on administrative procedure and public debate over how science informs federal health policy. Observers should watch appeal filings, any further court rulings, and near-term vaccine uptake data to assess whether the ruling stabilizes coverage or merely delays renewed policy shifts.
Sources
- The New York Times — Live coverage of U.S. government and court actions (news reporting)
- American Academy of Pediatrics — Official statements and policy (medical organization) (organization/advocacy)
- Robert Wood Johnson Foundation — Amicus brief participants and public-health analysis (nonprofit/foundation)
- Centers for Disease Control and Prevention — Advisory Committee structure and immunization schedule background (federal public-health agency)